Royal College of Surgeons in Ireland Coláiste Ríoga na Máinleá in Éirinn

StAR Research Lecturer Programme

Under the StAR Programme, RCSI prioritises the nurturing of research talent through the commitment of a wealth of resources, all focused on a collegial academic and teaching environment that encourages each RCSI researcher to develop and grow.

To coincide with the launch of FutureNeuro, the SFI Research Centre of Excellence for chronic and rare neurological diseases, RCSI is seeking an ambitious, visionary research lecturer to embark with us on the latest exciting phase in our research mission in neuroscience.

StAR Research Lecturer in Neuroscience

Post title: Research Lecturer - Neuroscience

Reports to: Head of Department or nominee

Location: FutureNeuro Research Centre, Royal College of Surgeons in Ireland (RCSI), Dublin

Salary and package: The salary for this position is €63,125 until the post is tenured as permanent academic lectureships (3-5 years).

In addition, RCSI will make an investment of up to €150,000 in your research, including a four-year PhD studentship and significant career development investment in the form of mentoring and protected research time.

The position provides an opportunity to participate in a team of world-leading neuroscientists in the highly prestigious FutureNeuro Research Centre for Chronic and Rare Neurological Diseases.

Term of office: Tenure track appointment up to five years (pending performance review). The applicant will receive a yearly progress review, and at the end of year 3, a major review will be undertaken to determine whether the position will be converted to a permanent post. The review will be overseen by a committee that is external to the Research Lecturer's academic department.

Apply now

FutureNeuro and neuroscience at RCSI

Up to one billion people worldwide suffer from brain diseases. In Europe, brain diseases represent 35% of the total burden of all disease, affecting 179 million patients and costing more than €800 billion per annum. Neuroscience and genetics research underpinned by remarkable new sequencing and imaging technologies have advanced our understanding of the pathomechanisms of these diseases.

FutureNeuro brings together multidisciplinary scientific teams with clinicians and industry to deliver advances in diagnostic medicine, personalised and network therapeutics, cross-linked by a national e-health infrastructure platform that is disease-focused.

The mission of FutureNeuro is to accelerate discoveries on genetic diagnosis and advanced molecular treatments supported by enabling e-health technology for chronic and rare neurological diseases. Building initially on internationally recognised strengths in epilepsy and motor neuron disease research, the centre aims to develop additional research programmes in other chronic and rare neurological diseases.

RCSI has a significant international track-record in the field of neuroscience. Examples of recent work by RCSI-based teams in the centre include breakthroughs in uncovering the patho-mechanisms underlying epilepsy development following brain injury, human brain imaging evidence of structural changes in epilepsy patients over time, exploring the role of epigenetics and noncoding RNAs in epilepsy, developing systems modelling and biomarkers in particular those related to the development and treatment of sporadic forms of epilepsy.

The RCSI-based members of the FutureNeuro Centre include:

  • Prof. David Henshall, FutureNeuro Centre Director, is a world-leading authority on cell death signaling pathways and the role of noncoding RNAs (microRNAs) in epilepsy.
  • Prof. Jochen Prehn, Chairman of the Department of Physiology and Medical Physics, has pioneered cell imaging and mathematical modeling of neural behavior and co-discovered the ALS risk gene ANG.
  • Prof. Gianpiero Cavalleri discovered the genetic predictor of serious adverse reactions to the commonly used epilepsy drug carbamazepine and plays a leading role in international pharmacogenomics and genetics consortia.

Other FutureNeuro Centre PIs bring expertise in neuronal stem cell technology (Prof Sanbing Shen NUIG), molecular technology in blood-brain barrier (Prof. Matthew Campbell TCD) and advanced detection of brain molecules in blood (Prof. Robert Forster, DCU). The PI team is complemented by eminent clinicians in the field of neuroscience - Prof. Orla Hardiman and Prof. Colin Doherty. Additionally, FutureNeuro is built on network of research active clinical collaborators based in Ireland's key paediatric and adult specialist centres for treatment of complex neurological diseases.

The FutureNeuro PI outstanding scientific achievements have created international reputations in key fields that underpin the Centre's research. The Group has published over 400 articles from 2010-2016 with over 60 international collaborators that received 7000+ citations including recent work in the highest impact journals in the world: Nature, Science, Nat Genet, Nat Med, Sci Trans Med and New Engl J Med. Members lead international consortia and major European initiatives. Income for 2016 was €35m.

FutureNeuro has a mandate to build successful industry partnerships with a view to commercialisation. To date, the center has developed multinational and indigenous partners across the three thematic areas, including its research on genomic interrogation for precision medicine, next-generation therapeutics with multi-targeting and disease-modifying actions and e-Health. FutureNeuro will expand it industry collaborations to scale the Centre and to address other neurological disease areas. Engagement with industry partners is a key element of all research roles.